Prescription medication · LAMA / LABA Combination

tiotropium/olodaterol

Also sold as Stiolto Respimat. Stiolto Respimat is used to treat chronic obstructive pulmonary disease (COPD).

Data updated 2026-05-15

3
InteractionsFew interactions
Rx
Availability

tiotropium/olodaterol (Stiolto Respimat) is a prescription LAMA / LABA Combination. Stiolto Respimat is used to treat chronic obstructive pulmonary disease (COPD).

Stiolto Respimat combines two medicines to help you breathe better if you have COPD. It is used long-term to manage your COPD symptoms.

Verify with FDA → · CMS NADAC pricing →

View Alternatives → Compare with Another Drug →

What it does

Stiolto Respimat is used to treat chronic obstructive pulmonary disease (COPD).

Common side effects

Common cold symptoms (nasopharyngitis), Cough, Back pain

Key warnings

Using LABA medicines like Stiolto Respimat without a steroid medicine can be dangerous if you have asthma.

The sections below are summarized in plain English from tiotropium/olodaterol's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Stiolto Respimat contains two medicines that open your airways. Tiotropium helps to relax the muscles around your airways. Olodaterol is a long-acting beta-agonist (LABA) that also relaxes airway muscles.

Serious Warnings

Using LABA medicines like Stiolto Respimat without a steroid medicine can be dangerous if you have asthma. Stiolto Respimat is not meant to treat asthma. Do not use Stiolto Respimat for sudden breathing problems. Using too much Stiolto Respimat can cause serious heart problems and may be fatal. If you have a bad reaction, like swelling or rash, stop using Stiolto Respimat and get medical help.

Known Drug Interactions

moderate olodaterol

Avoid administration of STIOLTO RESPIMAT with other anticholinergic-containing drugs. ( 7.6 ) 7.1 Adrenergic Drugs If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of olodaterol, one component of STIOLTO RESPIMAT, may be potentiated [see Warnings and Precautions (5.3 , 5.6 , 5.10 , 5.11) ] . Although the clinical significance of these effects is not known, caution is advised in the co-administration of STIOLTO RESPIMAT with non-potassium sparing diuretics.

Mechanism: Using two inhalers that contain the same medicine can cause you to have too much of the drug in your system. This can lead to a fast heartbeat, shakiness, or other heart-related problems.

moderate tiotropium

Avoid administration of STIOLTO RESPIMAT with other anticholinergic-containing drugs. ( 7.6 ) 7.1 Adrenergic Drugs If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of olodaterol, one component of STIOLTO RESPIMAT, may be potentiated [see Warnings and Precautions (5.3 , 5.6 , 5.10 , 5.11) ] . Although the clinical significance of these effects is not known, caution is advised in the co-administration of STIOLTO RESPIMAT with non-potassium sparing diuretics.

Mechanism: Both of these medicines contain the same type of drug, and taking them together can cause an overdose of those effects.

minor ketoconazole

7.7 Inhibitors of Cytochrome P450 and P-gp Efflux Transporter In a drug interaction study using the strong dual CYP and P-gp inhibitor ketoconazole, a 1.7-fold increase of olodaterol maximum plasma concentrations and AUC was observed [see Pharmacokinetics (12.3) ] .

Mechanism: Ketoconazole stops the body from breaking down the olodaterol part of this medicine properly. This leads to a buildup of the drug in your system, which could increase the risk of side effects.

This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.

Common Questions

Can I use Stiolto Respimat for asthma?
No, Stiolto Respimat is not indicated for asthma.
What should I do if Stiolto Respimat doesn't seem to be working?
Contact your doctor if your COPD symptoms worsen or if Stiolto Respimat is not providing relief.
Can I use a spacer with Stiolto Respimat?
No, Stiolto Respimat is designed to be used without a spacer.
How do I know when my Stiolto Respimat inhaler is empty?
The inhaler has a dose indicator that shows how many puffs are left. When it reaches zero, the inhaler will lock.
Can I use Stiolto Respimat for sudden breathing problems?
No, Stiolto Respimat is not a rescue inhaler. Use a short-acting beta-agonist for sudden symptoms.
What if I get Stiolto Respimat in my eyes?
Avoid spraying Stiolto Respimat in your eyes.
Can I use Stiolto Respimat with other inhalers?
Talk to your doctor about all the medicines you use, including other inhalers.
How long does Stiolto Respimat take to work?
Stiolto Respimat starts working quickly to open your airways, but it may take several weeks to feel the full effect.
Is Stiolto Respimat a steroid?
No, Stiolto Respimat does not contain a steroid.
How often should I clean my Stiolto Respimat inhaler?
Wipe the mouthpiece with a damp cloth weekly.
What are the common side effects of tiotropium/olodaterol?
The registry lists Common cold symptoms (nasopharyngitis), Cough, Back pain among the most-reported FAERS reaction terms for tiotropium/olodaterol. These counts are not an individual symptom assessment.
Does tiotropium/olodaterol interact with other medications?
The registry has 3 documented interaction rows for tiotropium/olodaterol. Notable source-record pairings include olodaterol, tiotropium, ketoconazole. These rows are not a complete medication review.
What drug class is tiotropium/olodaterol?
tiotropium/olodaterol belongs to the LAMA / LABA Combination drug class. It requires a prescription (Rx). Stiolto Respimat is used to treat chronic obstructive pulmonary disease (COPD).
What pregnancy or breastfeeding source fields are listed for tiotropium/olodaterol?
The FDA label for tiotropium/olodaterol contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Related Medications in LAMA / LABA Combination

Other drugs grouped near tiotropium/olodaterol - same-class peers and common alternatives.

aclidinium

Tudorza Pressair

Compare with tiotropium/olodaterol →

albuterol

Ventolin, ProAir

Albuterol is a drug that helps you breathe easier.

Compare with tiotropium/olodaterol →

albuterol/ipratropium

Combivent Respimat, DuoNeb

Combivent Respimat is a combination medicine that helps open your airways.

Compare with tiotropium/olodaterol →

beclomethasone

Qvar

Qvar Redihaler is an inhaled medicine that helps control asthma symptoms.

Compare with tiotropium/olodaterol →

benralizumab

Fasenra

Fasenra is a medicine that can help treat severe asthma and EGPA.

Compare with tiotropium/olodaterol →

Compare tiotropium/olodaterol vs aclidinium side-by-side →

Medication Guides

Understanding Drug Interactions

How CYP450 enzymes, inhibitors, and inducers affect your medications

Generic vs Brand Name Drugs

FDA requirements, cost savings, and when the difference matters

Narrow Therapeutic Index Drugs

FDA bioequivalence and label-record context for narrow therapeutic index medicines

Common Drug Interactions

Dangerous medication combinations and how to protect yourself

Save on tiotropium/olodaterol

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Check Prices on GoodRx →

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for tiotropium/olodaterol

The FDA label for tiotropium/olodaterol (sold under brand names such as Stiolto Respimat) classifies it as a prescription-only medication in the LAMA / LABA Combination class. Stiolto Respimat is used to treat chronic obstructive pulmonary disease (COPD). Official labeling lists 3 commonly reported side effects, including Common cold symptoms (nasopharyngitis), Cough, Back pain.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. The database also lists 3 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: June 30, 2025

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Read our methodology - how this data is sourced, computed, and verified.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page